Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Impatto del consumo regolare di uova e nutrienti delle uova fortificate sulla condizione di eczema negli individui di Singapore

10 novembre 2026 aggiornato da: Jung Eun Kim, National University of Singapore

Impatto del consumo regolare di uova e nutrienti delle uova arricchite sulla condizione di eczema negli individui di Singapore affetti da eczema

The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in Singapore individuals with eczema. The investigators hypothesize that egg consumption will improve eczema condition and nutrients fortified egg consumption will improve further improvements when compared to standard egg consumption in individuals with eczema

Panoramica dello studio

Descrizione dettagliata

This is a double-blind, randomized, parallel study and all subjects will complete a 12-week study period. Subjects will be tasked to consume nutrients-fortified eggs and regular eggs daily for 12 weeks. After which, subjects are assessed for changes in carotenoid status, antioxidant and anti-inflammatory biomarkers, skin and eye health measurements, and other biomarkers of health.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

43

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Singapore
      • Singapore, Singapore, Singapore, 117550
        • Department of Food Science and Techonology, Block S13

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 21 anni a 59 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. English-literate and able to give informed consent in English
  2. Male and female participants, aged between 21 and 59 inclusive
  3. Healthy individuals with no underlying condition or on regular medication
  4. BMI between 18.5-25 kg/m2
  5. Mild to moderate severity of eczema, which will also be determined using our questionnaires during the screening visit

Exclusion Criteria:

  1. Significant change in body weight (3 kg or more) in the past 3 months
  2. Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
  3. Known food allergy to eggs
  4. Taking dietary supplements which may impact the study results
  5. Having gastrointestinal disorders not suitable for the study
  6. Current smokers
  7. Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider, or 45ml of distilled spirit
  8. Taking lipid-lowering and blood pressure-controlling medications for less than 3 years
  9. Pregnant or lactating women, or planning to conceive in the next 6 months
  10. Unwilling to stop the medication of eczema during the study, either topical creams or oral medications
  11. Hierarchical link (professional and familial ties) with the research team members
  12. Participating in another clinical study
  13. Having blindness in one eye or more, eye diseases, retinal/lens/optical nerve surgery, or other eye conditions that may impact the study results
  14. Low-quality macular pigment optical density results were determined during the screening visit.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Regular egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 regular egg/day for 12 weeks.

Consumption of regular egg with habitual diet

Sperimentale: Nutrient-fortified egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 nutrient-fortified egg/day for 12 weeks.

Consumption of nutrient-fortified eggs with habitual diet

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Skin questionnaires - SCORing Atopic Dermatitis (SCORAD) Index
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

SCORing Atopic Dermatitis (SCORAD) Index is a clinical tool used to assess the severity of atopic dermatitis (AD), also known as eczema. This index can estimate participants' body surface area affected by burns (extent - A: percentage of body surface area affected), Intensity (B: clinical signs are assessed and scored on a scale from 0 (absent) to 3 (severe)), Subjective Symptoms (C: itch, sleep disturbance are evaluated based on the participants' report over the past three days, each scored on a scale from 0 (no symptom) to 10(severe symptom)).

The SCORAD index is calculated using the following formula:

SCORAD=A/5+7B/2+C

Interpretation Mild atopic dermatitis: SCORAD < 25 Moderate atopic dermatitis: SCORAD 25-50 Severe atopic dermatitis: SCORAD > 50

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Eczema Area and Severity Index (EASI) scoring system
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

EASI evaluates the extent and severity of eczema in four body regions: the head and neck, the trunk, the upper limbs, and the lower limbs.

The EASI score ranges from 0 to 72, with higher scores indicating more severe eczema:

0: No eczema 1-7: Mild eczema 8-21: Moderate eczema 22-50: Severe eczema 51-72: Very severe eczema

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Dermatology life quality index (DLQI)
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

DLQI is a dermatology-specific instrument used to measure the impact of skin diseases on patients' quality of life. Which assessed disease impact, monitor treatment effectiveness, guide clinical decision-making.

Interpretation of Scores:

0-1: No effect on patient's life 2-5: Small effect on patient's life 6-10: Moderate effect on patient's life 11-20: Very large effect on patient's life 21-30: Extremely large effect on patient's life

Week 0, week 3, week 6, week 9, week 12
Skin measurement - eczema related
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

Skin hydration - units arbitrary Corneometer®. Transepidermal water loss - units gram/hour. Sebum level - unit µg/cm2. Skin pH level - skin pH meter. Skin tape stripping: stratum corneum components assessed by immune dot blots

Week 0, week 3, week 6, week 9, week 12
Skin carotenoids status
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

Skin carotenoids concentration can be measured by Resonance Raman Spectroscopy, unit is skin carotenoid score, higher score means optimal, lower score means poor condition of skin carotenoids.

Week 0, week 3, week 6, week 9, week 12
Blood carotenoids levels
Lasso di tempo: Week 0, week 6, week 12

Blood carotenoids levels can be measured by High-Performance Liquid Chromatography, unit is μmol/L.

Week 0, week 6, week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Eye health - Macular Pigment Optical Density
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

A measurement of macular pigment of the eye using a heterochromatic flicker photometry device. The measurements are in arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Eye health - Visual acuity
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

Participants will read out letters on a ETDRS LogMAR chart at a fixed distance where letters becomes smaller as it goes down the chart. Tests results will be recorded in number of letters read, where the more letters the better the outcome.

Week 0, week 3, week 6, week 9, week 12
Eye health - Photostress recovery time
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

An ophthalmoscope will be used to shine a light into the participants eye for 10 seconds, and participants will be required to read letters off a chart the moment their vision returns to normal. The faster the recovery time, the better the outcome. Units will be in seconds

Week 0, week 3, week 6, week 9, week 12
Visual function questionnaire 25
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

A questionnaire to for participants to self-evaluate their perception of their current eye health based on general vision, ocular pain, near activities, distance activities, vision specific functions, driving, color vision and peripheral vision. The best possible score is 100 and worst possible score is 0.

Week 0, week 3, week 6, week 9, week 12
Concentration of tumour necrosis factor-α
Lasso di tempo: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Tumor necrosis factor-α results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of interleukin-6
Lasso di tempo: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of high-sensitivity C-reactive protein
Lasso di tempo: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. High-sensitivity C-reactive protein results will be obtained and presented in mg/L by commercial lab testing.

Week 0, week 6, week 12
Concentration of fasting blood glucose
Lasso di tempo: Week 0, week 6, week 12

Fasting blood glucose will be measured using commercial lab testing using participants' blood, units will be in mmol/L.

Week 0, week 6, week 12
Concentration of malondialdehyde
Lasso di tempo: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of malondialdehyde using commercially available enzyme-linked immunosorbent assay kits. Units for malondialdehyde will be in ng/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of 8-isoprostaglandin-F2α
Lasso di tempo: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of 8-isoprostaglandin-F2α using commercially available enzyme-linked immunosorbent assay kits. Units for 8-isoprostaglandin-F2α will be in µmol/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of insulin
Lasso di tempo: Week 0, week 6, week 12

Fasting blood insulin will be measured using commercial lab testing using participants' blood, units in μU/L.

Week 0, week 6, week 12
Percentage of glycated hemoglobin
Lasso di tempo: Week 0, week 6, week 12

Glycated hemoglobin will be measured using commercial lab testing from participant's blood, units in percent.

Week 0, week 6, week 12
Skin advanced glycation end products levels
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

Measurement of skin advanced glycation end products level using a skin autofluorescence device, where participants wlll be instructed to place their forearm over the device and a light will be shone and a reading can be captured by detecting fluorescence. The results will be presented as arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Blood advanced glycation end products levels
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

Participants will have their blood drawn by medical professionals at the Occupational Health Clinic. The blood will be processed and stored. Measurements will be done using ultra-performance liquid chromatography coupled with mass spectrometry techniques to determine the levels of advanced glycation end products. Units will be in μg/mL.

Week 0, week 3, week 6, week 9, week 12

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Dietary assessment
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

3-day food record will be used to assess participants' dietary intake for two weekdays and one weekend day before each clinical visit.

Week 0, week 3, week 6, week 9, week 12
Measurement of height
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

Height will be measured using height-weight scale and units will be in cm.

Week 0, week 3, week 6, week 9, week 12
Measurement of blood pressure
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

A blood pressure monitoring device available commercially will be used be to measure their systolic and diastolic blood pressure. Unit is mmHg.

Week 0, week 3, week 6, week 9, week 12
Measurement of weight
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

Weight will be measured using height-weight scale and units will be in kg.

Week 0, week 3, week 6, week 9, week 12
Measurement of waist circumference
Lasso di tempo: Week 0, week 3, week 6, week 9, week 12

Waist circumference will be measured using a measuring tape by a trained personnel, units in cm.

Week 0, week 3, week 6, week 9, week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Jung Eun Kim, PhD, RD, National University of Singapore

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 luglio 2024

Completamento primario (Effettivo)

27 ottobre 2025

Completamento dello studio (Effettivo)

1 dicembre 2025

Date di iscrizione allo studio

Primo inviato

7 aprile 2024

Primo inviato che soddisfa i criteri di controllo qualità

10 giugno 2024

Primo Inserito (Effettivo)

12 giugno 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

The link between participants' information data and the code will be kept confidential by the NUS research team or a trusted third party. Research data and results will only be collated in its coded format. All research data collected will be retained for a minimum of 10 years following the NUS Research Data Management Policy.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi